Cerebral Embolic Protection Devices (CEPDs) During Transcatheter Aortic Valve Implantation (TAVI): A Meta‐Analysis of Randomized Controlled Trials
Clinical Cardiology · 2026-04 · 49 (4)
DOI: 10.1002/clc.70309 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Clinical Cardiology, online erschienen am 23.04.2026. Verfasst von Mohamed Ibrahim Gbreel und 3 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, October 6 University, Giza, Egypt. Hauptthemen laut MEDLINE: Transcatheter Aortic Valve Replacement, Embolic Protection Devices, Intracranial Embolism, Aortic Valve Stenosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Aims
Transcatheter aortic valve implantation (TAVI) is associated with procedure‐related stroke. Cerebral embolic protection devices (CEPDs) are designed to reduce the risk of embolic debris reaching the brain; however, the evidence supporting their efficacy remains controversial. We aim to evaluate the efficacy and safety of CEPDs in patients undergoing TAVI.
Methods
Major databases were systematically searched up to April 2025. Only randomized controlled trials (RCTs) were included and critically appraised using the Cochrane Risk of Bias (ROB‐2) tool. We calculated risk ratios (RRs) with the 95% confidence intervals for the outcomes, and trial sequential analysis (TSA) was conducted to reduce the risk of false‐positive results due to random errors.
Results
Eight RCTs (11,589 patients) were analyzed. No significant difference was observed in overall stroke incidence between CEPD and control groups (0.92 (95% CI: 0.75–1.14; p = 0.40, I 2 = 0%), including disabling and non‐disabling strokes. Device‐specific analyses showed a non‐significant reduction in disabling stroke with the Sentinel device. All‐cause mortality, transient ischemic attacks, bleeding, acute kidney injury, delirium, and pacemaker implantation rates were similar between groups. CEPD use was linked to a transient improvement in cognitive function (MoCA scores) at 2–5 days post‐TAVI, but this effect was not sustained at later follow‐ups. TSA indicated that current evidence is insufficient to definitively refute CEPD efficacy.
Conclusion
CEPDs show no significant reduction in overall, disabling, or non‐disabling stroke, nor in all‐cause mortality post‐TAVI. Trial Registration This meta‐analysis was registered on PROSPERO. No.: CRD420251026208.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Medicine, October 6 University, Giza, Egypt.
- Faculty of Medicine, Ain Shams University, Cairo, Egypt.
- Theodor Bilharz Research Institute, Giza, Egypt.
- Department of Cardiology, University Hospital Rostock, Rostock, Germany.
ORCID-Profile: Mohamed Ibrahim Gbreel, Ahmed Samy Badran
Zitieren
APA
Gbreel, M. I., Badran, A. S., Hassan, M., & Balata, M. (2026). Cerebral Embolic Protection Devices (CEPDs) During Transcatheter Aortic Valve Implantation (TAVI): A Meta‐Analysis of Randomized Controlled Trials. Clinical Cardiology, 49(4). https://doi.org/10.1002/clc.70309
Vancouver
Gbreel MI, Badran AS, Hassan M, Balata M. Cerebral Embolic Protection Devices (CEPDs) During Transcatheter Aortic Valve Implantation (TAVI): A Meta‐Analysis of Randomized Controlled Trials. Clinical Cardiology. 2026;49(4). doi:10.1002/clc.70309
BibTeX
@article{Gbreel2026,
author = {Gbreel, Mohamed Ibrahim and Badran, Ahmed Samy and Hassan, Marwa and Balata, Mahmoud},
title = {Cerebral Embolic Protection Devices (CEPDs) During Transcatheter Aortic Valve Implantation (TAVI): A Meta‐Analysis of Randomized Controlled Trials},
journal = {Clinical Cardiology},
year = {2026},
volume = {49},
number = {4},
doi = {10.1002/clc.70309}
}
EUVIMED